Table 1.

Patient characteristics

	n = 47 (IQR/%)
Age (median, yrs)	68 (60‐71)
Metastasize status, n
Primary M+ diagnosis	30 (64%)
M+ after primary treatment	13 (28%)
Unknown	4 (8%)
Primary treatment, n
Radical prostatectomy	13 (28%)
External radiation therapy	14 (30%)
Brachytherapy	1 (2%)
Prior systemic treatment, n
Androgen deprivation	47 (100%)
Chemotherapy	8 (17%)
Treatment at inclusion, n
Docetaxel	22 (47%)
Cabazitaxal	2 (4%)
Abiraterone	16 (34%)
Enzalutamide	7 (15%)
Samples available for analysis, n
Baseline	47 (100%)
2nd timepoint	47 (100%)
3rd timepoint	37 (79%)
4th timepoint	25 (53%)
sPSA, ng/mL (median)
Baseline PSA	108 (35.0‐220)
2nd timepoint	38.1 (3.6‐140.0)
3rd timepoint	34.0 (3.5‐76.2)
4th timepoint	19.0 (2.9‐155.0)
Follow‐up, months (median)	18 (11‐26)
Patients died of PCa, n	18 (38%)